CIK 0001636282
- Large accelerated filer
Spyre Therapeutics, Inc.
Sign in to watch- Ticker
- SYRE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464312787
- Phone
- +1 617-651-5940
- Business address
- 221 CRESCENT STREET, BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aeglea BioTherapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,349,597
- in 6 filings, $12.3M under 10b5-1 plans
Net −$12,349,597. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-22 | HENDERSON MICHAEL THOMAS Director | Sale 10b5-1 | −20,000 | $100.00 | $2.0M | 68,606 |
| 2026-05-27 | HENDERSON MICHAEL THOMAS Director | Grant or award · Stock Option (Right to Buy) | +8,026 | 8,026 | ||
| 2026-05-08 | HENDERSON MICHAEL THOMAS Director | Sale 10b5-1 | −2,404 | $72.57 | $174K | 166,202 |
| 2026-05-08 | HENDERSON MICHAEL THOMAS Director | Sale 10b5-1 | −33,513 | $73.72 | $2.5M | 132,689 |
| 2026-05-08 | HENDERSON MICHAEL THOMAS Director | Sale 10b5-1 | −24,814 | $74.76 | $1.9M | 107,875 |
| 2026-05-08 | HENDERSON MICHAEL THOMAS Director | Sale 10b5-1 | −19,269 | $75.35 | $1.5M | 88,606 |
| 2026-01-21 | HENDERSON MICHAEL THOMAS Director | Other acquisition | +63,227 | 168,606 | ||
| 2025-05-29 | HENDERSON MICHAEL THOMAS Director | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2025-01-10 | HENDERSON MICHAEL THOMAS Director | Other acquisition | +105,379 | 105,379 | ||
| 2024-05-14 | HENDERSON MICHAEL THOMAS Director | Grant or award · Stock Option (Right to Buy) | +11,323 | 11,323 |
Page 1 of 1 · 10 trades